Search Results
Results found for "Family B GPCRs"
- Discovery of 3(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligand
August 2022 "Abstract Sigma receptor is a transmembrane non-GPCR protein expressed mainly in the endoplasmic Read more at the source #DrGPCR #GPCR #IndustryNews
- X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
Read more at the source #DrGPCR #GPCR #IndustryNews
- Dr. Ross Bathgate becomes Scientific co-founder of LASEREDD Therapeutics
position as Scientific co-founder LASEREDD Therapeutics" Ross Bathgate Read more at the source #DrGPCR #GPCR
- Sosei Heptares recently hosted their annual Scientific Advisory Board (SAB)
Read more at the source #DrGPCR #GPCR #IndustryNews
- Tectonic Therapeutic Strengthens Leadership Team
Tectonic Therapeutic, Inc. a pre-clinical stage biotechnology company transforming the discovery of novel GPCR-targeted Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex raises $4.2 million in equity financing
issuance and will expire five years from their date of issuance. " Read more at the source #DrGPCR #GPCR
- Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ...
Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR1 Read more at the source #DrGPCR #GPCR #IndustryNews
- From Student to Mentor: What Alessandro Nicoli Learned About Leading in Science
As the lab grew, so did his responsibilities: from building computational models of GPCRs to guiding Join the GPCR scientist network and connect with peers shaping the next wave of discovery. ________ Keyword Cloud: #Mentoring #ScienceLeadership #PhDmentorship #GPCR #PhDlife #AcademicLeadership #LabCulture
- Third Rock pushes newest fund over $1B line as it marks 15 years in venture capital
Read more at the source #DrGPCR #GPCR #IndustryNews
- Orion Shares New Data on its Latest Best-in-Class Drug Candidate
discovery and development company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs Vice-President Drug Discovery, will present Orion’s novel technology for targeting undrugged peptidergic GPCRs discovery platform, one of the fastest drug discovery solutions in the industry for targeting peptidergic GPCRs antagonist, OB-004, demonstrating the ability of this powerful platform to rapidly identify best-in-class GPCR Read more at the source #DrGPCR #GPCR #IndustryNews
- Michel Bouvier appointed Knight of the Ordre national du Québec
Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Presents Clinical And Research Results At ENDO 2022
Read more at the source #DrGPCR #GPCR #IndustryNews
- Novel interaction between neurotrophic factor-α1/carboxypeptidase E and serotonin receptor, 5-HTR1E,
"Protecting neurons from death during oxidative and neuroexcitotoxic stress is key for preventing cognitive dysfunction. We uncovered a novel neuroprotective mechanism involving interaction between neurotrophic factor-α1 (NF-α1/carboxypeptidase E, CPE) and human 5-HTR1E, a G protein-coupled serotonin receptor with no previously known neurological function. Co-immunoprecipitation and pull-down assays confirmed interaction between NFα1/CPE and 5-HTR1E and 125I NF-α1/CPE-binding studies demonstrated saturable, high-affinity binding to 5-HTR1E in stably transfected HEK293 cells (Kd = 13.82 nM). Treatment of 5-HTR1E stable cells with NF-α1/CPE increased pERK 1/2 and pCREB levels which prevented a decrease in pro-survival protein, BCL2, during H2O2-induced oxidative stress. Cell survival assay in β-arrestin Knockout HEK293 cells showed that the NF-α1/CPE-5-HTR1E-mediated protection against oxidative stress was β-arrestin-dependent. Molecular dynamics studies revealed that NF-α1/CPE interacts with 5-HTR1E via 3 salt bridges, stabilized by several hydrogen bonds, independent of the serotonin pocket. Furthermore, after phosphorylating the C-terminal tail and intracellular loop 3 (ICL3) of NF-α1/CPE-5-HTR1E, it recruited β-arrestin1 by forming numerous salt bridges and hydrogen bonds to ICL2 and ICL3, leading to activation of β-arrestin1. Immunofluorescence studies showed 5-HTR1E and NF-α1/CPE are highly expressed and co-localized on cell surface of human hippocampal neurons. Importantly, knock-down of 5-HTR1E in human primary neurons diminished the NF-α1/CPE-mediated protection of these neurons against oxidative stress and glutamate neurotoxicity-induced cell death. Thus, NF-α1/CPE uniquely interacts with serotonin receptor 5-HTR1E to activate the β-arrestin/ERK/CREB/BCL2 pathway to mediate stress-induced neuroprotection." Read full article
- Dr. Thomas P. Sakmar receives an honorary doctorate from Karolinska Institute
and grateful to receive honorary doctorate yesterday from Karolinska Institute and celebrate with my family Read more at the source #DrGPCR #GPCR #IndustryNews
- Targeting the M1 muscarinic receptor in neurodegenerative disease
Translational Sciences Associate Director at Sosei Heptares, recently presented at the Keystone Symposia GPCR Read more at the source #DrGPCR #GPCR #IndustryNews
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
Read more at the source #DrGPCR #GPCR #IndustryNews
- Domain Therapeutics Raises $42m Series A Financing
specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs Read more at the source #DrGPCR #GPCR #IndustryNews
- John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Modulation of Striatal Adenosinergic Function by HTL0041178, a Selective GPR52 Agonist
control neuropsychiatric symptoms in conditions such as schizophrenia. " Read more at the source #DrGPCR #GPCR
- Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of ...
These molecules are then evaluated at unprecedented speed and scale on hundreds of GPCR targets simultaneously Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
Read more at the source #DrGPCR #GPCR #IndustryNews
- Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
Changes to Drive the Company Through the Next Stage of its Evolution "New team focused on expanding its GPCR-focused Read more at the source #DrGPCR #GPCR #IndustryNews
- Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- ShouTi Pharma CEO Dr. Raymond Stevens was interviewed by Moira Gunn of the NPR TechNation podcast
April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...
– Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs pharmacokinetics of CFTX-1554 in healthy subjects (NCT05260658). " Read more at the source #DrGPCR #GPCR
